Can TCN2 rs1801198 reduce cellular B12 delivery despite high serum B12?

The TCN2 rs1801198 (776C>G) genetic variant significantly alters vitamin B12 biodistribution, decoupling systemic serum measurements from actual cellular availability. This discordant relationship is highly relevant in clinical scenarios where standard B12 blood panels may falsely indicate nutritional adequacy.

Clinical evidence of diagnostic discordance

• Serum vs. Cellular Status: Total serum B12 primarily measures extracellular cobalamin, which can remain normal or even highly elevated (particularly during supplementation) despite tissue-level deficiency.
• Biomarker Profile: Patients carrying the rs1801198 variant can exhibit functional intracellular deficiency alongside normal-to-high total serum B12, marked by elevations in the functional biomarkers methylmalonic acid (MMA) and homocysteine.

Mechanistic pathways

• Reduced Transporter Efficiency: The rs1801198 polymorphism encodes a transcobalamin II protein with decreased binding and transport efficiency.
• HoloTC Depletion: This structural alteration impairs the formation of active holotranscobalamin (holoTC)—the specific form of B12 capable of cellular uptake—resulting in lower circulating holoTC and diminished cellular delivery.

Red-cell maturation impacts

• Impaired Erythropoiesis: Intracellular cobalamin is a vital cofactor for DNA synthesis during red blood cell development. Localized cellular deprivation in the bone marrow disrupts erythroid progenitor division.
• Morphological Changes: This impaired maturation manifests as subtle, subclinical megaloblastic shifts, leading to elevations in mean corpuscular volume (MCV) and red cell distribution width (RDW).

Bottom line

The TCN2 rs1801198 variant impairs cellular vitamin B12 delivery, allowing intracellular deficiency and subtle red-cell maturation changes (such as elevated MCV) to occur concurrently with normal or high serum B12 levels.